|
Shield Therapeutics PLC on Wednesday said it achieved operating cash flow positivity in the fourth quarter of 2025, as it guided an operating profit in 2026. The Newcastle, England-based commercial-stage pharmaceutical company said it generated positive cash flow in the fourth quarter, as it noted total revenue of around $50 million for 2025, up around 56% from revenue and other income of $32 million in 2024. Accrufer net revenues rose to $13.5 million in the quarter, up 21% from $11.2 million. Accrufer is Shield’s oral treatment for those with iron deficiency with or without anaemia. Accrufer prescriptions rose to around 64,000 in the quarter from around 41,000 a year prior, ‘representing the highest dispenses in any quarter since launch’, the company said. Shield added that the net selling price for the treatment fell 6.3% to $222 from $237, owing to an increase in covered rebated prescriptions. Shield reported cash and cash equivalents of $11.6 million at December 31, up 35% from $8.6 million at September 30, noting it achieved positive operating cash flow of $1 million. It noted this was excluding receipt of proceeds of $2.0 million from the amended senior secure debt financing announced in the quarter. Its shares were down 6.9% at 10.47 pence on Wednesday afternoon in London. Looking ahead, the company said it expects to deliver an operating profit in 2026. ‘Reaching cash flow positivity is a significant milestone in the company’s history that allows us to continue to grow our business without the need for further external financing,’ said Chief Executive Anders Lundstrom. ‘The efforts of the sales teams, together with our strategic marketing initiatives, delivered our strongest year on record for Accrufer, achieving new highs in prescription volumes, net selling price, and revenues. Accrufer’s strong performance in the fourth quarter along with a strengthened balance sheet exiting 2025 gives us the momentum and financial flexibility to achieve our 2026 strategic priorities.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
